Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Prithviraj Bose is an assistant professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center. After obtaining his medical degree from the University of Calcutta in Kolkata, India, where he attended the Calcutta Medical College, Dr. Bose completed an internship in internal medicine at a University of Washington affiliate in Spokane, Wash., and residency at the Henry Ford Hospital in Detroit, Mich., followed by a fellowship in hematology and oncology at the University of Oklahoma Health Sciences Center in Oklahoma City, Okla. He then went on to join the hematology/oncology faculty at Virginia Commonwealth University (VCU) in Richmond, Virg., where he was an assistant professor of medicine and a member of the NCI-designated VCU Massey Cancer Center.
At VCU, Dr. Bose partnered with Dr. Steven Grant, an internationally recognized molecular pharmacologist, to develop laboratory-based, rational combinations of novel, targeted agents into early phase clinical trials in the myeloid malignancies, chiefly acute myeloid leukemia. His clinical practice encompassed all hematologic malignancies, with a focus on the leukemias. At MDACC, Dr. Bose’s major clinical and research focus is on MPNs. He works closely with Dr. Srdan Verstovsek, Professor in the Department of Leukemia and chief of the section of MPNs. The two have authored a number of articles together in peer-reviewed journals and other fora and continue to do so. Dr. Bose is also heavily involved in the design and management of clinical trials for patients with MPNs, and also in other areas of MPN research.
Dr. Bose has published over 100 peer-reviewed journal articles, book chapters and scientific meeting abstracts. His work has appeared in The New England Journal of Medicine and Williams’ Hematology. Additionally, Dr. Bose has served as a peer-reviewer for multiple hematology and oncology journals, such as The Lancet Oncology, The Lancet Haematology, Thrombosis and Haemostasis, British Journal of Haematology, Leukemia and Lymphoma, Journal of the National Cancer Institute, Expert Opinion on Investigational Drugs, European Journal of Cancer, Cancer Biology and Therapy and Clinical Lymphoma, Myeloma and Leukemia. In 2011, Dr. Bose was selected to participate in the American Society of Hematology’s prestigious Clinical Research Training Institute. In 2013, he was granted permanent residence in the United States in the select “outstanding researcher” (first preference) category.